Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1994-12-14
1996-12-31
Criares, Theodore J.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
324212, 324210, 324422, 324448, A61K 3144, A61K 31445, A61K 31395, A61K 3140
Patent
active
055894828
ABSTRACT:
Benzothiophenes and related compounds of the formula ##STR1## are estrogen agonists which are useful for treating prostatic and diseases, obesity and bone loss in male animals.
REFERENCES:
patent: 4133814 (1979-01-01), Jones et al.
patent: 4358593 (1982-11-01), Jones et al.
patent: 4380635 (1983-04-01), Peters
patent: 4418068 (1983-11-01), Jones et al.
patent: 4732912 (1988-03-01), Pilgrim et al.
patent: 4859585 (1989-08-01), Sonnenschein et al.
patent: 4970237 (1990-11-01), Jensen et al.
patent: 5021414 (1991-06-01), Pilgrim et al.
patent: 5075321 (1991-12-01), Schreiber et al.
patent: 5147880 (1992-09-01), Jones et al.
patent: 5196435 (1993-03-01), Clemens et al.
patent: 5393763 (1995-02-01), Black et al.
Marsh, et al. "Management of Menopause" British Medical Bulletin (1992), vol. 48, No. 2 pp. 426-428.
Prince, et al. "Prevention of Postmenopausal Osteoporosis" The New England Journal of Medicine, Oct. 14, 1991 vol. 325, No. 17 pp. 1190-1193.
Nabulshi, et al. "Association of Hormone-Replacement Therapy with Various Cardiovascular Rish Factors in Pos-Menopausal Women" The New England Journal of Medicine Apr. 15, 1993, vol. 328 No. 15, pp. 1069-1075.
Tikkanen, et al. "Natural Estrogen as an Effective Treatment for Type-II Hyperlipoproteinaemia in Postmenopausal Women" The Lancet, Sep. 2, 1978, pp. 490-493.
Osteoporosis Conference, Script No. 1812/13 Apr. 16th/20th 1993, pp. 29-30 PJB Publishers Ltd.
Jones, et al. "Antiestrogens.2..sup.1 Activity Studies in a Series of 3-Aroyl-2-arylbenzo[b]thiophene Derivatives Leading to [6-Hydroxy-2-(4-hydroxyphenyl)benzol[b]theine-3-yl][4-2-(2-piperidinyl) ethoxy]-phenyl]methanone Hydrochloric (LY156758), a Remarkably Effective Estrogen Antagonist with only Minimal Intrinsic Estrocgencity" J. Med. Chem., 1984, 27, 1057-1066.
Hong, et al. "Effects of Estrogen Replacement Therapy on Serum Lipid Values and Angiographically Defined Coronary Artery Disease in Postmenopausal Women" The American Journal of Cardiology, Jan. 15, 1992 vol. 69 pp. 176-178.
Recker, Robert R., Clinical Review 41, Current Therapy for Osteoporosis, Journal of Clinical Endocrinology and Metabolism vol. 76, No. 1 pp. 14-16, 1991.
Carter, S. K. et al, Chemotherapy of Cancer, 2.sup.nd Edition, pp. 361-365, (1987).
Benson Gregg C.
Brokke Mervin E.
Criares Theodore J.
Pfizer Inc.
Richardson Peter C.
LandOfFree
Benzo-thiophene estrogen agonists to treat prostatic hyperplasia does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Benzo-thiophene estrogen agonists to treat prostatic hyperplasia, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Benzo-thiophene estrogen agonists to treat prostatic hyperplasia will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1142299